Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

jupiter

Rank: Treasurer [?]

Points: 619 [?]

Votes: 20 Score: 3.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

in response to

Resverlogix Clinical Candidate Apabetalone Featured as a Potential COVID-19 Treatment in Recent Publication

BearDownAZ

posted on Mar 24, 2020 02:05PM

Thanks for posting George and Bear.

"The article titled: “A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing” by Gordon et al, identified BRD2/4 as a binding partner of viral protein E. Apabetalone was shown to disrupt this interaction."

I do not see the justification for the statement "Apabetalone was shown to disrupt this interaction" in the article. This would seem to be a result of some follow-up work done in one of labs testing the anti-viral properties of the candidate drugs. Did I miss something?